These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 6110769)

  • 21. Effects of 1-(4-nitrophenyl)-2-isopropylaminoethanol (INPEA) and propranolol and their dextro-isomers on hemodynamic and metabolic responses to isoproterenol in dogs.
    Nishimura T; Kita S; Abiko Y
    J Pharmacol Exp Ther; 1983 Aug; 226(2):595-602. PubMed ID: 6688273
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analysis of hepatic metabolism affecting pharmacokinetics of propranolol in humans.
    Kiriyama A; Honbo A; Iga K
    Int J Pharm; 2008 Feb; 349(1-2):53-60. PubMed ID: 17765415
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Pharmacokinetics of propranolol, phenytoin and lidocaine in hypercholesterolemic rabbits].
    Vinçon G; Ploux D; Pehourcq F; Albin H
    J Pharmacol; 1983; 14(1):47-55. PubMed ID: 6834851
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Correlation between pharmacological response, kinetics of plasma concentration and in vitro receptor affinities exemplified with beta-adrenoceptor blocking drugs.
    Wellstein A; Palm D
    Methods Find Exp Clin Pharmacol; 1984 Oct; 6(10):641-4. PubMed ID: 6151037
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Propranolol increases the threshold for lidocaine-induced convulsions in awake rats: a direct effect on the brain.
    Nakamura T; Oda Y; Takahashi R; Tanaka K; Hase I; Asada A
    Anesth Analg; 2008 May; 106(5):1450-5, table of contents. PubMed ID: 18420859
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Receptor binding of propranolol is the missing link between plasma concentration kinetics and the effect-time course in man.
    Wellstein A; Palm D; Pitschner HF; Belz GG
    Eur J Clin Pharmacol; 1985; 29(2):131-47. PubMed ID: 3000793
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mechanism-based modeling of rebound tachycardia after chronic l-propranolol infusion in spontaneous hypertensive rats.
    Brynne L; Paalzow LK; Karlsson MO
    J Pharmacol Exp Ther; 1999 Aug; 290(2):664-71. PubMed ID: 10411576
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vasorelaxing effects of propranolol in rat aorta and mesenteric artery: a role for nitric oxide and calcium entry blockade.
    Priviero FB; Teixeira CE; Toque HA; Claudino MA; Webb RC; De Nucci G; Zanesco A; Antunes E
    Clin Exp Pharmacol Physiol; 2006; 33(5-6):448-55. PubMed ID: 16700877
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics of propranolol in the cat and comparisons with humans and three other species.
    Weidler DJ; Jallad NS; Garg DC; Wagner JG
    Res Commun Chem Pathol Pharmacol; 1979 Oct; 26(1):105-14. PubMed ID: 117534
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Plasma insulin levels and beta-adrenoceptor antagonists. Relevance of the steric configuration of beta-adrenoceptor antagonists to their effect on glucose tolerance.
    Beck A; Conca W; Bacher S; Raberger G
    Naunyn Schmiedebergs Arch Pharmacol; 1983 Sep; 324(1):46-9. PubMed ID: 6138714
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics and pharmacodynamics of propranolol stereoisomers in hyperthyroid patients.
    Tawara K; Kawashima K; Ishikawa H; Yamamoto K; Saito K; Ebihara A; Yoshida S
    Eur J Clin Pharmacol; 1981 Feb; 19(3):197-203. PubMed ID: 6894282
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Stereoselective glucuronidation of beta-blocking agents, 1-tert-butylamino-3-(2,3-dimethylphenoxy)-2-propanol (D-32) and propranolol, in animals, in vivo and in vitro].
    Honma S; Ito T; Matsuki Y
    Yakugaku Zasshi; 1986 May; 106(5):406-13. PubMed ID: 2876088
    [No Abstract]   [Full Text] [Related]  

  • 33. No stereoselective first-pass hepatic extraction of propranolol.
    Jackman GP; McLean AJ; Jennings GL; Bobik A
    Clin Pharmacol Ther; 1981 Sep; 30(3):291-6. PubMed ID: 7273593
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Stereospecific and circadian-phase-dependent kinetic behavior of d,l-, l-, and d-propranolol in plasma, heart, and brain of light--dark-synchronized rats.
    Lemmer B; Bathe K
    J Cardiovasc Pharmacol; 1982; 4(4):635-44. PubMed ID: 6181339
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics of long acting propranolol. Implications for therapeutic use.
    Nace GS; Wood AJ
    Clin Pharmacokinet; 1987 Jul; 13(1):51-64. PubMed ID: 3304770
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of chlorpromazine on the disposition and beta-adrenergic blocking activity of propranolol in the dog.
    Bai SA; Abramson FP
    J Pharmacokinet Biopharm; 1984 Jun; 12(3):333-49. PubMed ID: 6502474
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics of propranolol during pregnancy.
    O'Hare MF; Kinney CD; Murnaghan GA; McDevitt DG
    Eur J Clin Pharmacol; 1984; 27(5):583-7. PubMed ID: 6519163
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Exercise increases plasma concentrations of (R)- and (S)-propranolol.
    Stoschitzky K; Schumacher M; Stark G; Dimai HP; Stauber R; Stoschitzky P; Krejs GJ; Klein W; Lindner W
    Eur J Clin Pharmacol; 1996; 50(4):339-42. PubMed ID: 8803530
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Racemic (R,S)-propranolol versus half-dosed optically pure (S)-propranolol in humans at steady state: Hemodynamic effects, plasma concentrations, and influence on thyroid hormone levels.
    Stoschitzky K; Lindner W; Egginger G; Brunner F; Obermayer-Pietsch B; Passath A; Klein W
    Clin Pharmacol Ther; 1992 Apr; 51(4):445-53. PubMed ID: 1563214
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Disposition of propranolol isomers in mice.
    Levy A; Ngai SH; Finck AD; Kawashima K; Spector S
    Eur J Pharmacol; 1976 Nov; 40(1):93-100. PubMed ID: 991931
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.